JP2020507625A - ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 - Google Patents
ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP2020507625A JP2020507625A JP2019563697A JP2019563697A JP2020507625A JP 2020507625 A JP2020507625 A JP 2020507625A JP 2019563697 A JP2019563697 A JP 2019563697A JP 2019563697 A JP2019563697 A JP 2019563697A JP 2020507625 A JP2020507625 A JP 2020507625A
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- optionally substituted
- groups
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455639P | 2017-02-07 | 2017-02-07 | |
| US62/455,639 | 2017-02-07 | ||
| US201762594799P | 2017-12-05 | 2017-12-05 | |
| US62/594,799 | 2017-12-05 | ||
| PCT/GB2018/050343 WO2018146469A1 (en) | 2017-02-07 | 2018-02-07 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507625A true JP2020507625A (ja) | 2020-03-12 |
| JP2020507625A5 JP2020507625A5 (enExample) | 2021-03-11 |
Family
ID=61226606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563697A Pending JP2020507625A (ja) | 2017-02-07 | 2018-02-07 | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11028067B2 (enExample) |
| EP (1) | EP3580215A1 (enExample) |
| JP (1) | JP2020507625A (enExample) |
| KR (1) | KR20190115013A (enExample) |
| CN (1) | CN110382486A (enExample) |
| AU (1) | AU2018218519B2 (enExample) |
| BR (1) | BR112019016223A2 (enExample) |
| CA (1) | CA3051537A1 (enExample) |
| MA (1) | MA47451A (enExample) |
| MX (1) | MX392000B (enExample) |
| WO (1) | WO2018146469A1 (enExample) |
| ZA (1) | ZA201904967B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| CA3051644A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| MX389800B (es) | 2017-02-07 | 2025-03-20 | Oblique Therapeutics Ab | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer |
| US20210038577A1 (en) * | 2018-02-12 | 2021-02-11 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5697282A (en) * | 1979-12-19 | 1981-08-05 | Duphar Int Res | Nitrothiophene compound* its manufacture and its composition |
| WO2007137255A2 (en) * | 2006-05-22 | 2007-11-29 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| WO2010138820A2 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| WO1995029897A1 (en) | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| JP2002515023A (ja) | 1995-08-24 | 2002-05-21 | ビーエーエスエフ アクチェンゲゼルシャフト | Ｎ−複素環化合物、その製造用中間体、それを含む組成物及び有害菌類防除にそれを使用する方法 |
| WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| JP2001519345A (ja) | 1997-10-02 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| DK0930302T3 (da) | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| US20100048713A1 (en) | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| CA2647338A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| EP2535059A4 (en) | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF) |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| EP2811990B1 (en) | 2012-02-10 | 2017-10-25 | The Board of Regents of The University of Texas System | Modulators of exchange proteins directly activated by camp (epacs) |
| US8946418B1 (en) | 2013-07-10 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| MX392900B (es) | 2017-02-07 | 2025-03-24 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer |
| MX389800B (es) | 2017-02-07 | 2025-03-20 | Oblique Therapeutics Ab | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer |
| CA3051644A1 (en) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
-
2018
- 2018-02-07 JP JP2019563697A patent/JP2020507625A/ja active Pending
- 2018-02-07 AU AU2018218519A patent/AU2018218519B2/en not_active Ceased
- 2018-02-07 CN CN201880010198.8A patent/CN110382486A/zh active Pending
- 2018-02-07 MA MA047451A patent/MA47451A/fr unknown
- 2018-02-07 KR KR1020197024694A patent/KR20190115013A/ko not_active Ceased
- 2018-02-07 BR BR112019016223A patent/BR112019016223A2/pt not_active IP Right Cessation
- 2018-02-07 US US16/484,039 patent/US11028067B2/en not_active Expired - Fee Related
- 2018-02-07 EP EP18705461.4A patent/EP3580215A1/en not_active Withdrawn
- 2018-02-07 WO PCT/GB2018/050343 patent/WO2018146469A1/en not_active Ceased
- 2018-02-07 MX MX2019009351A patent/MX392000B/es unknown
- 2018-02-07 CA CA3051537A patent/CA3051537A1/en active Pending
-
2019
- 2019-07-29 ZA ZA2019/04967A patent/ZA201904967B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5697282A (en) * | 1979-12-19 | 1981-08-05 | Duphar Int Res | Nitrothiophene compound* its manufacture and its composition |
| WO2007137255A2 (en) * | 2006-05-22 | 2007-11-29 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| WO2010138820A2 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 6, no. 4, JPN6021049083, 1958, pages 369 - 373, ISSN: 0004660644 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019128045A3 (enExample) | 2021-03-09 |
| RU2019128045A (ru) | 2021-03-09 |
| MA47451A (fr) | 2019-12-18 |
| US11028067B2 (en) | 2021-06-08 |
| CA3051537A1 (en) | 2018-08-16 |
| EP3580215A1 (en) | 2019-12-18 |
| MX392000B (es) | 2025-03-21 |
| AU2018218519A1 (en) | 2019-08-15 |
| US20200223819A1 (en) | 2020-07-16 |
| ZA201904967B (en) | 2023-12-20 |
| KR20190115013A (ko) | 2019-10-10 |
| MX2019009351A (es) | 2019-09-19 |
| AU2018218519B2 (en) | 2021-08-05 |
| BR112019016223A2 (pt) | 2020-04-07 |
| CN110382486A (zh) | 2019-10-25 |
| WO2018146469A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6636153B2 (ja) | ピリジン及び癌治療におけるそれらの使用 | |
| US11028067B2 (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| JP2021006579A (ja) | トリプトファンジオキシゲナーゼ（ｉｄｏ１とｔｄｏ）の阻害剤及び治療におけるその使用 | |
| US20220119348A1 (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| JP2020506244A (ja) | ヘテロシクリルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 | |
| JP2020507624A (ja) | スルフィニルピリジンおよび癌の治療におけるそれらの使用 | |
| RU2772935C2 (ru) | Гетероарилсульфонил-замещенные пиридины и их применение при лечении рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210125 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220302 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220801 |